Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in ...

Nearly one in 20 people who had a SARS-CoV-2 infection go on to experience myalgic encephalomyelitis/chronic fatigue syndrome ...

New findings from the NIH RECOVER Initiative suggest that SARS-CoV-2 infection may be associated with an increased risk of ME ...

Adriel Chen and Devi Sridhar discuss the outbreak of Paediatric Inflammatory Multisystem Syndrome in 2020 and consider what lessons we can learn In mid-March 2020 and into April 2020, paediatric wards ...

The risk for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is increased following COVID-19, according to study findings.

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug for Covid-19. Credit: seksan Mongkhonkhamsao ...

Shionogi will receive $375 million to develop a long-acting protease inhibitor designed to prevent SARS-CoV-2 infection in ...

Jake Sullivan, the outgoing national security adviser, is asking a panel of outside experts to examine the government’s ...

A recent University of Utah Health study found that 4.5% of Covid-19 survivors developed chronic fatigue syndrome, a ...

According to the researchers, Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition that is ...

Levels of respiratory illnesses in the Sheboygan area are high, on trend with regional and state data, according to Sheboygan ...

Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection.